Literature DB >> 15607913

Cyclotron production of Ac-225 for targeted alpha therapy.

C Apostolidis1, R Molinet, J McGinley, K Abbas, J Möllenbeck, A Morgenstern.   

Abstract

The feasibility of producing Ac-225 by proton irradiation of Ra-226 in a cyclotron through the reaction Ra-226(p,2n)Ac-225 has been experimentally demonstrated for the first time. Proton energies were varied from 8.8 to 24.8 MeV and cross-sections were determined by radiochemical analysis of reaction yields. Maximum yields were reached at incident proton energies of 16.8 MeV. Radiochemical separation of Ac-225 from the irradiated target yielded a product suitable for targeted alpha therapy of cancer.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15607913     DOI: 10.1016/j.apradiso.2004.06.013

Source DB:  PubMed          Journal:  Appl Radiat Isot        ISSN: 0969-8043            Impact factor:   1.513


  26 in total

1.  Actinium-225 for Targeted α Therapy: Coordination Chemistry and Current Chelation Approaches.

Authors:  Nikki A Thiele; Justin J Wilson
Journal:  Cancer Biother Radiopharm       Date:  2018-06-11       Impact factor: 3.099

Review 2.  Actinium-225 in targeted alpha-particle therapeutic applications.

Authors:  David A Scheinberg; Michael R McDevitt
Journal:  Curr Radiopharm       Date:  2011-10

Review 3.  Chemical aspects of metal ion chelation in the synthesis and application antibody-based radiotracers.

Authors:  Eszter Boros; Jason P Holland
Journal:  J Labelled Comp Radiopharm       Date:  2018-03-12       Impact factor: 1.921

4.  64Cu-Intraperitoneal Radioimmunotherapy: A Novel Approach for Adjuvant Treatment in a Clinically Relevant Preclinical Model of Pancreatic Cancer.

Authors:  Yukie Yoshii; Hiroki Matsumoto; Mitsuyoshi Yoshimoto; Yoko Oe; Ming-Rong Zhang; Kotaro Nagatsu; Aya Sugyo; Atsushi B Tsuji; Tatsuya Higashi
Journal:  J Nucl Med       Date:  2019-03-08       Impact factor: 10.057

5.  Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.

Authors:  Markus Essler; Florian C Gärtner; Frauke Neff; Birgit Blechert; Reingard Senekowitsch-Schmidtke; Frank Bruchertseifer; Alfred Morgenstern; Christof Seidl
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-01-12       Impact factor: 9.236

6.  Targeted alpha-radionuclide therapy of functionally critically located gliomas with 213Bi-DOTA-[Thi8,Met(O2)11]-substance P: a pilot trial.

Authors:  D Cordier; F Forrer; F Bruchertseifer; A Morgenstern; C Apostolidis; S Good; J Müller-Brand; H Mäcke; J C Reubi; A Merlo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-02-16       Impact factor: 9.236

Review 7.  Molecular targeted α-particle therapy for oncologic applications.

Authors:  Thaddeus J Wadas; Darpan N Pandya; Kiran Kumar Solingapuram Sai; Akiva Mintz
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

Review 8.  Realizing the potential of the Actinium-225 radionuclide generator in targeted alpha particle therapy applications.

Authors:  Matthias Miederer; David A Scheinberg; Michael R McDevitt
Journal:  Adv Drug Deliv Rev       Date:  2008-04-23       Impact factor: 15.470

Review 9.  Overview of the Most Promising Radionuclides for Targeted Alpha Therapy: The "Hopeful Eight".

Authors:  Romain Eychenne; Michel Chérel; Férid Haddad; François Guérard; Jean-François Gestin
Journal:  Pharmaceutics       Date:  2021-06-18       Impact factor: 6.321

Review 10.  Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine.

Authors:  Rubel Chakravarty; Cerise M Siamof; Ashutosh Dash; Weibo Cai
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-08-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.